- Cytokinetics Incorporated (NASDAQ:CYTK) presented results from Cohort 4 of REDWOOD-HCM Phase 2 trial of aficamten in patients with non-obstructive hypertrophic cardiomyopathy (nHCM).
- At ten weeks, patients in Cohort 4 experienced significant improvements in NT-proBNP, with an average decrease of 66%.
- High-sensitivity troponin I level also improved significantly proportional to baseline at each study visit.
- Related: FDA Rejects Cytokinetics’ Heart Failure Treatment Candidate.
- An improvement of ≥1 NYHA Functional Class was observed in 22 of 41 (54%) patients.
- After the 2-week washout period, NT-proBNP and high-sensitivity troponin I levels returned to baseline.
- Additionally, 48-week data from the FOREST-HCM study were also presented at the meeting.
- New data through 48 weeks of treatment showed that aficamten was associated with significant reductions in the average resting LVOT-G (mean change from baseline (SD) = -32 (28) mmHg, and Valsalva LVOT-G (mean change from baseline (SD) = -47 (28) mmHg.
- Treatment with aficamten also resulted in significant improvements in NYHA class, with 88% of patients experiencing a ≥1 NYHA Functional Class improvement, and significant improvements in NT-proBNP, with an average decrease of 70% from baseline to Week 48.
- Price Action: CYTK shares closed at $41.95 on Friday.
Rocket Lab Successfully Completes First Test Fire Of Reused Rutherford Engine
The engine was launched to space on Rocket Lab's 26th Electron mission ‘There And Back Again' in May 2022 before it was returned to Earth, caught by a helicopter and recovered at sea, and refurbished
